WEBULL
WebtradeDownload

How BioMarin’s Navepegritide Settlement and Royalty Deal with Ascendis Could Shape BioMarin (BMRN) Investors

Simply Wall St · 3d ago
  • On 31 August 2026, Ascendis Pharma A/S announced a binding global settlement and license agreement with BioMarin Pharmaceutical, granting Ascendis a non-exclusive, worldwide, royalty-bearing license to continue developing and commercializing navepegritide-related products, while both companies agreed to dismiss all related legal proceedings and BioMarin waived certain regulatory rights and exclusivities.
  • Under this deal, BioMarin stands to receive meaningful royalties on YUVIWEL and other navepegritide-related sales across key markets through May 2030, transforming a legal dispute into a long-term revenue-sharing arrangement.
  • We’ll now examine how securing royalty income on YUVIWEL sales fits into and potentially reshapes BioMarin’s existing investment narrative.

AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

BioMarin Pharmaceutical Investment Narrative Recap

To own BioMarin, you need to believe in its ability to turn a focused rare-disease portfolio into durable, profitable growth while managing high R&D and operating costs. The Ascendis settlement does not change the central near term catalyst around VOXZOGO label expansions and uptake, but it modestly improves visibility on royalty income and removes a legal and IP overhang that had added to portfolio and regulatory risk.

The recent acquisition of Alesta Therapeutics, adding ALE1 for hypophosphatasia, helps broaden BioMarin’s skeletal disease pipeline at a time when investors are closely watching VOXZOGO concentration and competitive threats. Set alongside the new YUVIWEL royalty stream, this move highlights how management is trying to diversify future revenue drivers and support earnings growth ahead of key VOXZOGO regulatory milestones.

Yet despite these positives, investors should still pay close attention to the risk that portfolio concentration and rising expenses could...

Read the full narrative on BioMarin Pharmaceutical (it's free!)

BioMarin Pharmaceutical's narrative projects $4.9 billion revenue and $1.3 billion earnings by 2029.

Uncover how BioMarin Pharmaceutical's forecasts yield a $87.85 fair value, a 35% upside to its current price.

Exploring Other Perspectives

BMRN 1-Year Stock Price Chart
BMRN 1-Year Stock Price Chart

Some of the most optimistic analysts were already assuming BioMarin could reach about US$5.5 billion in revenue and roughly US$2.1 billion in earnings by 2029, so if you are comparing that bullish view with the new YUVIWEL royalty deal and the risk of stricter rare disease pricing rules, it is worth remembering that expectations can differ widely and may need updating as this story evolves.

Explore 4 other fair value estimates on BioMarin Pharmaceutical - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.